|
Market Cap (16-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 14 September 2022, 12:52. The announcement is not marked as price sensitive, and is 22 page(s) in length and 1.38MB in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.054% short sold according to ASIC data. It was ranked the 524th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Investor presentation, 14 September 2022 | 14 September 2022, 12:52 |
| Rett Syndrome NDA accepted for Priority Review by FDA | 13 September 2022, 9:12 |
| S&P DJI Announces September 2022 Quarterly Rebalance | 2 September 2022, 17:01 |
| Half-year shareholder update | 24 August 2022, 9:28 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 